Article
Passenger mutations as a target for the personalized therapy of cancer
2018-11-11
Abstract excerpt
The American FDA approved the first comprehensive NGS diagnostic assay for cancer at the end of 2017, leading the way to personalised therapy of cancer and the massive employ of bioinformatics (https://www.fda.gov/downloads/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/ ucm584603.pdf ). In NGS-detected genes from cancer patients, driver and passenger mutations can be distinguished. The former prov...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 634a5772-d50d-5e1b-bf46-a06ff0f0618f
- DOI
- 10.7287/peerj.preprints.27338v1
